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Heart disease remains a major cause of death
despite advances in medical technology. Heart-
regenerative therapy that uses pluripotent stem cells
(PSCs) is a potentially promising strategy for patients
with heart disease, but the inability to generate highly
purified cardiomyocytes in sufficient quantities has
been a barrier to realizing this potential. Here, we
report a nongenetic method for mass-producing
cardiomyocytes frommouse and human PSC deriva-
tives that is based on the marked biochemical differ-
ences in glucose and lactate metabolism between
cardiomyocytes and noncardiomyocytes, including
undifferentiated cells. We cultured PSC derivatives
with glucose-depleted culture medium containing
abundant lactate and found that only cardiomyo-
cytes survived. Using this approach, we obtained
cardiomyocytes of up to 99% purity that did not
form tumors after transplantation. We believe that
our technological method broadens the range of
potential applications for purified PSC-derived cardi-
omyocytes and could facilitate progress toward
PSC-based cardiac regenerative therapy.
INTRODUCTION
Heart disease is a common and deadly disease, and heart-
regenerative therapy is a promising therapeutic strategy for
some patients (Passier et al., 2008). Pluripotent stem cells
(PSCs) including embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs) are potential sources for produc-
tion of therapeutic cardiomyocytes (Burridge et al., 2012; Taka-
hashi et al., 2007; Thomson et al., 1998). A typical human leftCeventricle contains roughly 6 3 109 cardiomyocytes; thus, nearly
1 3 109 de novo cardiomyocytes would be required per patient
for this type of repair (Hattori and Fukuda, 2012). However, PSC-
based approaches carry a high risk of tumor formation due to
contamination of residual PSCs in the therapeutic cell prepara-
tions. Therefore, obtaining highly purified cardiomyocytes will
be key for achieving therapeutic success in applying these cells.
Procedures involving density-gradient centrifugation (La-
flamme et al., 2007; Xu et al., 2006), genetic modification
(Fijnvandraat et al., 2003; Gassanov et al., 2004; Hidaka et al.,
2003; Klug et al., 1996), and nongenetic methods that use a
mitochondrial dye (Hattori et al., 2010) or antibodies to specific
cell-surface markers (Dubois et al., 2011; Uosaki et al., 2011)
have been established for cardiomyocyte enrichment. However,
none of thesemethods are ideal for the therapeutic application of
PSC-derived cardiomyocytes because of drawbacks including
insufficient purity, genotoxicity, and the use of fluorescence-
activated cell sorting (FACS) and/or antibodies.
Glucose is the main source of energy and anabolic precursors
in various mammalian cells. It is converted by glycolysis into
pyruvate and/or lactate via glucose-6-phosphate (G6P; a source
of nucleotides) and 3-phosphoglycerate (a source of some
amino acids) for generation of two ATP molecules without the
need for oxygen. Pyruvate is further utilized in the mitochondrial
tricarboxylic acid (TCA) cycle for production of 36 ATPmolecules
via oxidative phosphorylation (OXPHOS). Cardiomyocytes
efficiently produce energy from several substrates including
glucose, fatty acids, and lactate viaOXPHOS. Interestingly, there
are marked changes between energy substrate utilization by
cardiomyocytes before and after birth. The fetal heart has
a higher capacity for lactate uptake than the adult heart (Fisher
et al., 1981) and uses lactate as a major energy source (Neely
and Morgan, 1974; Werner and Sicard, 1987) by exploiting
the lactate-rich environment created by the placenta (Burd
et al., 1975).
In this study, we took advantage of the unique metabolic
properties of cardiomyocytes to develop an efficient andll Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc. 127
Figure 1. Distinct Metabolic Differences
Between Cardiomyocytes and ESCs in
Transcriptome and Fluxome Analyses
(A) Metabolic pathway map summarizing the
results from gene array and [13C]-labeled glucose
fluxome analyses. Gene names shown in red or
blue boxes indicate the mRNA expression levels
increased more than 2-fold in cardiomyocytes or
ESCs, respectively. The bar graphs represent the
detected levels of [13C]-labeled metabolites in
cardiomyocytes (red bar) and ESCs (blue bar) (n =
4). All units are nmol per 1.0 3 107 cells. All data
were obtained from independent experiments.
(B) Total [13C]-labeled metabolites of cardio-
myocytes (red bar) and ESCs (blue bar) in each
key pathway (n = 4).
(C) Secreted [13C]-labeled lactate concentration in
the media of cardiomyocytes (red bar) and ESCs
(blue bar) (n = 4). All data were obtained from
independent experiments.
*p < 0.05; **p < 0.01. Data are shown as mean ±
SD. All the abbreviations are shown in Table S1.
See also Figure S1 and Table S1.
Cell Stem Cell
Metabolic Selection for PSC-Derived Cardiomyocytesnoninvasive environmental approach for their purification from
PSC cultures.
RESULTS
Integrated Transcriptomic and Metabolomic Analyses
Highlight Distinct Metabolic Differences between
Cardiomyocytes and Other Proliferating Cells
To find metabolism-related genes that are differentially ex-
pressed between undifferentiated stem cells and cardiomyo-
cytes, we performed comparative transcriptome analyses of
undifferentiated mouse ESCs and neonatal mouse cardiomyo-
cytes purified by the ‘‘mitochondrial method’’(Hattori et al.,128 Cell Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc.2010) (Figures S1A and S1B available on-
line). The results for cardiomyocytes re-
vealed markedly higher expression of
genes encoding enzymes involved in the
TCA cycle than the undifferentiated
ESCs and, in turn, lower expression of
genes involved in the pentose phosphate,
amino acid synthesis, and lipid synthesis
pathways (Figure 1A and Table S1). Next,
we conducted a fluxome analysis (Ki-
noshita et al., 2007; Shintani et al., 2009)
to trace a range of metabolites derived
from [13C]-labeled glucose in neonatal
rat cardiomyocytes, mouse ESCs, a
hepatocyte cell line (HepG2), and a skel-
etal myoblast cell line (C2C12). [13C]-
labeled intermediate metabolites of the
glycolytic, pentose phosphate, and
amino acid synthesis pathways were
subsequently found at higher levels in
ESCs, HepG2, and C2C12 cells than in
cardiomyocytes (Figures 1A, 1B, and
S1C and Table S1). ESCs, HepG2, andC2C12 cells also discarded more lactate than cardiomyocytes
did (Figure 1C and Figure S1D). In contrast, cardiomyocytes
took up pyruvate intomitochondria, andmost [13C]-labeled inter-
mediate metabolites of the TCA cycle were significantly higher in
cardiomyocytes than in ESCs (Figure 1A). These transcriptome
and fluxome analyses highlighted a dynamic difference in the
metabolic fates of lactate between cell types (Figure S1E).
More specifically, lactate was discarded by noncardiomyocytes
but preferentially used in TCA metabolism by cardiomyocytes.
We hypothesized that cells mainly dependent on glycolysis
might not be able to survive under glucose-depleted and
lactate-abundant conditions, whereas cardiomyocytes would
survive by using lactate as an alternative energy source.
Figure 2. Cell Viabilities of Various Cells under Glucose-Depleted and Lactate-Supplemented Conditions
(A) Cultured neonatal rat cardiomyocytes and mouse ESCs were exposed to glucose-depleted media supplemented with lactate, and their viabilities were
assessed with the LIVE/DEAD kit, which indicates viable cells with green fluorescence and dead cells with nuclear red fluorescence.
(B) Time course of viability in neonatal rat cardiomyocytes (red), mouse ESCs (blue), and MEFs (green) under glucose-free conditions with and without lactate
(n = 6). Solid lines indicate the glucose-free and lactate-supplemented condition, and dashed lines indicate the glucose-free without lactate condition. All data
were obtained from independent experiments.
(C) Noncardiomyocytes including C2C12, skeletal myotubes, and primary cultured neurons were exposed to glucose-free conditions with and without lactate,
and their viabilities were assessed with the LIVE/DEAD kit. The time courses of viability were plotted in the line graphs (right) (all cells; n = 4). Red lines indicate the
glucose-free and lactate-supplemented condition, and black lines indicate the glucose-free without lactate condition. The inset in primary neurons represents
immunocytochemical staining with an antibody to bIII-tubulin (red) and with DAPI (blue).
Scale bars represent 100 mm (A and C). Data are shown as mean ± SD. See also Figure S2.
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Conditions Can Purify Cardiomyocytes from Mouse
and Human PSC Derivatives
To test our hypothesis, we exposed neonatal rat cardiomyo-
cytes, mouse ESCs, primary peripheral lymphatic cells, primary
fetal neurons, primary mouse embryonic fibroblasts (MEFs),
C2C12 cells (myoblasts and myotubes), hepatocytes (HepG2),
and renal cells (HEK293) to glucose-depleted conditions with
and without various concentrations of lactate. Every type of
cell died within 96 hr in the glucose-depleted conditions, and
as expected, supplementation with lactate only prolonged the
survival of cardiomyocytes (Figures 2A, 2B, 2C and S2). WeCenamed this special culture condition for the growth of cardio-
myocytes the ‘‘lactate method.’’
We next applied the lactate method to purifying human
PSC-derived cardiomyocytes. First, we optimized the time
course of the method for human ESC (hESC)-derived cardio-
myocytes. Using time-lapse imaging, we observed that 7 days’
exposure of hESC- and human iPSC (hiPSC)-derived attached
embryoid bodies (EBs) to glucose-free conditions supplemented
with 4 mM lactate selectively enriched for beating cells (Movie
S1). Second, we confirmed that days 7–8 of culture were the
best time points for harvesting the cells, as shown in Figure 3A.
To optimize the lactate concentration, we measured the viabilityll Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc. 129
Figure 3. Purification of Cardiomyocytes under Glucose-Depleted and Lactate-Supplemented Conditions
(A) Representative FACS analyses for a-actinin expression in the hESC-derived cells duringmetabolic selection. Control indicates hESC-derived cells after 2 days
of differentiation that do not contain any cardiomyocytes.
(B and C) Representative phase-contrast and immunofluorescent staining for a-actinin in the nonpurified hESC-derived EBs (B, left) and for a-actinin and Nkx2.5
in purified hESC (KhES-2)-derived cardiomyocytes (hESC-CMs) (B, right) and purified hiPSC (253G4)-derived cardiomyocytes (hiPSC-CMs) (C). Arrows indicate
a-actinin-positive cells.
(D) Representative immunofluorescent staining for a-actinin (red) in the hESC (KhES-2 and KhES-3)- and hiPSC (201B7)-derived dispersed cells before (upper
left) and after (upper right, lower panels) metabolic selection. The cell nuclei are stained by DAPI (blue).
(E) Percentage of a-actinin-positive cardiomyocytes in the hESC (KhES-2 and KhES-3)- and hiPSC (201B7 and 253G4)-derived dispersed cells before and after
metabolic selection. All data were obtained from independent experiments.
(F) Numbers of a-actinin-negative noncardiomyocytes (green) and a-actinin-positive cardiomyocytes (red) in the hESC-derived dispersed cells before (n = 5)
and after (n = 5) metabolic selection (left graph). The right graph represents only a-actinin-positive cardiomyocytes. All data were obtained from independent
experiments.
Scale bars represent 50 mm (D, insets), 100 mm (B, right; C and D, lower panels), and 500 mm (B, left; D, upper panels). **p < 0.01. Data are shown as mean ± SD.
See also Figure S3 and Movies S1, S2, and S3.
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Metabolic Selection for PSC-Derived Cardiomyocytesof purified hESC-derived cardiomyocytes exposed to glucose-
depleted conditions with various concentrations of lactate
for 6 days; we found the lowest numbers of dead cells in
4 mM lactate (Figure S3A). We further tested for the ideal period
of differentiation using the lactate method and found that
20–30 days of differentiation produced the highest reproduc-
ibility, purity, and yield of cardiomyocytes. To determine why
this period is optimal, we investigated the proliferative activity130 Cell Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc.of EBs on various differentiation days (days 14–60) using a
5-ethynyl-20-deoxyuridine (EdU) incorporation assay. The per-
centage of EdU-incorporated cells markedly decreased after
day 30 (Figure S3B), implying that proliferating cells are sensitive
to the lactate method. The optimized condition efficiently en-
riched for globally contracting aggregates in a time-dependent
manner (Figure S3C and Movie S2). Concomitantly, messenger
RNA (mRNA) expression of the cardiomyocyte-related gene
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Metabolic Selection for PSC-Derived CardiomyocytesMYH6 increased, while that of the pluripotency-related gene
POU5F1 (Figure S3D) decreased abruptly. In addition, the
mRNAs for noncardiac genes (NANOG, MYOD, AFP, and
MAP2) were completely eliminated, and those for other cardio-
myocyte-related genes (ACTC1 and NKX2.5) were significantly
enriched (Figures S3E and S3F). We also observed clumps of
purified cardiomyocytes in the adhered condition (Figures 3B
and 3C). We dispersed the clumps and cultured the cells therein
and then evaluated their purity before and after metabolic
selection. The percentages of a-actinin-positive cells before
and after metabolic selection were 8.1 ± 2.9% (n = 10) and
98.3 ± 0.9% (n = 10), respectively (Figures 3D and 3E). We also
confirmed the efficacy of the lactate method using other hESC
(KhES-3) and hiPSC (201B7 and 253G4) lines. As shown in
Figures 3D and 3E, the purities were determined as 98.9 ± 0.3,
95.5 ± 1.3, and 96.5 ± 2.0%, respectively. To identify selective
events in KhES-2 and iPSCs (253G4 and 201B7), we obtained
global gene-expression patterns for the PSC-derived EBs and
purified hESC-derived cardiomyocytes. We categorized the
expressed genes following the gene ontology consortium and
found both similarities and differences among EBs derived
from three cell lines (Ashburner et al., 2000). One possible expla-
nation for the differences is that the derived EBs contain various
types of cells that are eventually eliminated by the lactate-purifi-
cation method (Figures S3G and S3H). In our system, 4.0 3 106
hESCs differentiated into 6.2 ± 2.5 3 106 (n = 5) cells containing
6.3 ± 2.3 3 105 (n = 5) a-actinin-positive cardiomyocytes, and
4.7 ± 1.8 3 105 (n = 5) a-actinin-positive cardiomyocytes were
finally purified via the lactate method. Therefore, the yield-based
efficiency of our lactate method for hESCs was 74.4 ± 12.1%
(Figure 3F). To directly compare the yield-based efficiencies
between the lactate method and our previous mitochondrial
method, we evaluated the yield and found 52.9 ± 12.8% recovery
of cardiomyocytes in our previous mitochondrial method
(Figure S3I). To determine the types of noncardiomyocyte cells
remaining after metabolic selection, we performed immunocyto-
chemical screening and found that most of the cells were
smooth muscle actin (SMA)-positive (Figure S3J). Interestingly,
a-actinin- and SMA-double-positive cells were also found
(data not shown), consistent with a previous report that immature
cardiomyocytes express SMA (Cle´ment et al., 2007).
We then applied the lactate method to mouse ESCs using
lactate concentrations and timings optimized through similar
preliminary experiments for mouse cells. EBs attached to the
dishes were exposed to glucose-depleted and 1 mM lactate-
supplemented conditions. After 7 days of selection, we recov-
ered the surviving cells by collagenase digestion and transferred
them into new fibronectin-coated plates (Movie S3). Immunoflu-
orescence staining revealed that most of the surviving cells were
positive for the cardiac markers a-actinin and GATA4 (99.4 ±
0.6% purity, n = 5) (Figure S3K).
Cardiomyocytes Showed High Lactate Uptake and Used
Lactate for Metabolic-Energy Production
Why do only cardiomyocytes survive under the lactate-method
condition? To address this question, we first compared the
[14C]-lactate uptake activity of neonatal rat and human ESC-
derived cardiomyocytes, ESCs, MEFs, and noncontracting
EBs, and found that both cardiomyocyte populations showedCehigher levels of activity than the other cells (Figures 4A and
4C). We then measured the changes in intracellular ATP levels
in cardiomyocytes and other cells under lactate-method condi-
tions and found that the levels in mouse ESCs, MEFs, and non-
contracting EBs fell abruptly, whereas those in neonatal rat and
purified human ESC-derived cardiomyocytes were sustained for
significantly longer (Figures 4B and 4D). These results indicated
that cardiomyocytes, but not noncardiomyocytes, can effec-
tively uptake and use lactate to maintain ATP levels.
Lactate supplementation has the potential to cause acidifica-
tion either intracellularly or in the medium, which could lead to
cellular damage. We therefore investigated whether 4 mM
lactate supplementation affects extra- and intracellular pH
values. The extracellular pH values were stable at 7.5 following
1 hr of incubation in a 5% CO2 incubator (Figure S4A). The intra-
cellular pH values of cardiomyocytes, mouse ESCs, MEFs, and
C2C12 myoblasts were not affected by supplementation with
4mM lactate, but all were significantly decreased by the addition
of 20 mM lactate (Figures S4B and S4C). Lactate can be trans-
ported by monocarboxylic acid transporters (MCTs), of which
subtype 1 is abundantly expressed in muscle cells and localizes
at both the plasma and mitochondrial inner membrane (Hashi-
moto et al., 2006). For investigation of the significance of
MCT1 expression for lactate uptake in cardiomyocytes, the cells
were treated with MCT1 inhibitor a-cyano-4-hydroxycinnamate
(a-CHC) (Sonveaux et al., 2008) under glucose-free and
lactate-rich conditions. The lactate-induced prolonged survival
of cardiomyocytes under glucose-free conditions was largely
abolished by the MCT1 inhibitor, despite the lack of a-CHC
toxicity, suggesting that lactate uptake via MCT1 plays a major
role in the long-term survival of cardiomyocytes under metabolic
selection (Figure 4E). To investigate why cardiomyocytes can
effectively take up lactate, we checked the expression levels of
MCT1 in cardiomyocytes and ESCs but could not find a marked
difference between the two (Table S1). We then performed elec-
tron microscopy on the hESCs and their derivative cardiomyo-
cytes, as well as mitochondrial staining of hESC-derived cells.
The cardiomyocytes showed substantially higher numbers of
mitochondria than ESCs and other noncardiomyocytes (Figures
S4D and S4E). Because MCTs are passive transporters, we
suggest that a major mechanism underlying the enhanced
lactate uptake in cardiomyocytes could be the concentration
gradients generated by effective lactate consumption via the
highly active TCA cycle.
We further investigated how lactate is metabolized in various
types of cells. We performed lactate fluxome analysis in mouse
ESCs, hESC-derived EBs, MEFs, and neonatal rat cardiomyo-
cytes under glucose-depleted conditions for short (30 min)
periods. As expected, high levels of [2,4,5-13C]-citrate,
[3,4-13C]-succinate, and [2,3,4-13C]-malate were detected in
cardiomyocytes, whereas the ESCs, hESC-derived EBs, and
MEFs showed only small amounts of these metabolites,
suggesting that exogenous lactate is more efficiently metabo-
lized via the TCA cycle in cardiomyocytes than in noncardiomyo-
cytes, including ESCs (Figure 5 and Figure S5). To our surprise,
[13C]-labeled glycolytic intermediates including G6P were
observed in both cardiomyocytes and ESCs. These were even-
tually consumed in the pentose phosphate pathway for produc-
tion of inosine, guanosine, and adenosine monophosphates.ll Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc. 131
Figure 4. Lactate Uptake and Energetic
Homeostasis in Various Types of Cells
under Glucose-Depleted and Lactate-Sup-
plemented Conditions
(A and C) [14C]-labeled lactate uptake abilities in
(A) mouse ESCs, MEFs, and rat neonatal car-
diomyocytes (n = 3) and (C) in noncontracting
hESC-derived EBs and purified hESC-CMs
(n = 3). All data were obtained from independent
experiments.
(B and D) Intracellular ATP levels in (B) the mouse
ESCs,MEFs, and neonatal cardiomyocytes (n = 3),
and (D) in noncontracting hESC-derived EBs and
purified hESC-CMs (n = 3) under glucose-
depleted and lactate-supplemented conditions.
Relative ATP levels are indicated as percentages
of the levels in untreated samples. All data were
obtained from independent experiments.
(E) Cultured neonatal rat cardiomyocytes were
exposed to glucose-free with lactate conditions
supplemented with MCT1 inhibitor (a-CHC,
5 mM), and their viabilities were visualized using
the LIVE/DEAD kit (left). The time course of the
cardiomyocyte viabilities under different culture
conditions is shown (right). Chain and solid
red lines indicate glucose-depleted and lactate-
supplemented medium supplemented with (n = 4)
and without (n = 6) MCT1 inhibitor, respectively.
The dashed red line indicates the glucose-
depleted without lactate condition (n = 6). The blue
solid line indicates high-glucose medium supple-
mented with MCT1 inhibitor (n = 4). All data were
obtained from independent experiments.
Scalebar represents100mm(E). *p<0.05; **p<0.01.
Data are shown as mean ± SD. See also Figure S4.
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Metabolic Selection for PSC-Derived CardiomyocytesLong-period (24 hr) fluxome analysis in viable cardiomyocytes
also detected [5-13C]-labeled reduced (GSH) and [4,5,6,7,8,
10-13C]-labeled oxidized glutathione (GSSG), indicating that
glutamate, glycine, and/or cysteine were also synthesized from
the lactate (Figure 5 and Table S2).
Purified hESC-Derived Cardiomyocytes Showed High
Proliferative Capacity
We next investigated the proliferative capacity of mouse and
human ESC-derived cardiomyocytes purified using metabolic
selection. Some of the purified cardiomyocytes expressed
Ki67 antigen (Figure 6A) and showed EdU-incorporation activi-
ties (Figure 6B). For directly assessing the rate of karyokinesis
and cytokinesis after metabolic selection, the purified hESC-
derived aggregates were completely dissociated and then
seeded sparsely onto the MEF-layered dishes. Counting of
immunocytochemically a-actinin-positive cells after 2, 4, 6, and
8 days revealed that the purified cardiomyocytes could prolif-
erate up to 2.5-fold in 8 days, and the fraction of multinuclear
cardiomyocytes increased over time compared with the second
day (Figure 6C).
Purified Human PSC-derived Cardiomyocytes Showed
Physiologically Relevant Action-Potential
Configurations and Drug Responses
Action-potential recording using glass microelectrodes revealed
that the purified hESC-derived cardiomyocytes had nodal- (14 of132 Cell Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc.76), atrial- (23 of 76), or ventricular-like (39 of 76) action potentials
(Figure 6D and Figure S6A).We next evaluated their chronotropic
response to the b-agonist isoproterenol and muscarinic agonist
carbamylcholine using the multielectrode array (MEA) system;
the former agent increased the beating frequency, whereas the
latter decreased it, both in a dose-dependentmanner (Figure 6E).
We also found that beat frequency could be modulated by
temperature (Figure S6B), and intracellular [Ca2+] recording
using Fluo-4 dye also revealed that the purified hESC-derived
cardiomyocytes showed spontaneous and synchronized Ca2+
oscillations (Figure S6C).
Transplanted Purified Cardiomyocytes Did Not
Form Tumors
Finally, for investigation of the potential tumorigenicity of the
purified cardiomyocyte populations, 1,000 undifferentiated
hESCs, 2.0 3 105 nonpurified hESC-derived cardiomyocytes,
or the same number of purified cells were transplanted into the
testes of immunocompromised nonobese diabetic severe com-
bined immunodeficient (NOD-SCID)mice. Twomonths later, 9 of
10 (90%), 8 of 20 (40%), and 0 of 20 mice developed tumors,
respectively (Figure 6F and Figure S6D). For further verification
of the absence of residual undifferentiated cells, nonpurified
and purified dispersed hESC-derived cells (2.0 3 105) were
cultured on MEFs under PSC maintenance culture conditions
(colony formation assay) for 4 days. Nonpurified hESC-derived
cells formed Oct3/4- or Tra1-60-positive piled-up colonies, but
Figure 5. Mechanisms Underlying the Lactate-Mediated Survival of Cardiomyocytes
Fluxome analysis of the short-term (30 min) and long-term (24 hr) administration of [13C]-labeled lactate under glucose-depleted conditions in neonatal
cardiomyocytes and ESCs (ESCs, n = 4; cardiomyocytes, n = 3). The relationships between the kinds of bars, kinds of cell, and labeling conditions are shown in
the upper left. All data were obtained from independent experiments. The bold red arrow on the right indicates a possible reflux pathway from malate to G6P. All
units are nmol per 1.0 3 107 cells. *p < 0.05; **p < 0.01. Data are shown as mean ± SD. PEP, phosphoenolpyruvate. See also Figure S5 and Table S2.
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Figure S6E). To demonstrate the PSC-elimination capacity of
the lactate method, we used a commercially available kit based
on magnetic-beads-activated cell sorting with a Tra1-60 anti-
body. This experiment confirmed the apparent superiority of
the lactate method in eliminating stem cells compared to the
tested method (Figure S6F).
DISCUSSION
There are several approaches available for obtaining enriched
cardiomyocyte populations from human PSCs. Ma et al. (2011)
performed genetic-modification-based purification of cardio-
myocytes (achieving >98% cardiomyocyte purity) from hiPSC
derivatives, using the intrinsicMYH6gene to express ablasticidin
S resistance gene. Dubois et al. (2011) used a surface protein,
signal-regulatory protein alpha (SIRPA), as a cardiac-specific
marker in hiPSC derivatives prepared through a highly cardio-Cegenic differentiation procedure. They purified cardiomyocytes
(up to 98% purity) via FACS from sources comprising 40%–
50% cardiomyocytes. The method we report here is a simple
medium-exchanging procedure that enabled cardiomyocyte
purification of up to 99% from a cell source comprising only
10% cardiomyocytes, with an estimated recovery of cardiomyo-
cytes of 74.4 ± 12.1%, based on direct cell count before and
after purification. Previously we reported a mitochondrial
method for purifying cardiomyocytes to >99% purity via FACS.
Our direct comparison of these two methods revealed a higher
cardiomyocyte-yield-based efficiency for the lactate method
than for the mitochondrial method. The lactate method has
quantitative and economic advantages relative to other existing
cardiomyocyte-purification methods by virtue of its simplicity
and ease of application.
One question that arose from our studies is why ESCs die
within a few hours under the lactate method but cardiomyocytes
survive for much longer, even though both cell types use lactatell Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc. 133
Figure 6. Characterization of ESC-Derived Cardiomyocytes after Metabolic Selection
(A) Immunofluorescent staining for a-actinin (green) and Ki67 (red) in the purified mouse (top) and human (bottom) ESC-CMs.
(B) EdU-positive cells (green) in purified hESC-CMs.
(C) Numbers of hESC-derived dispersed cardiomyocytes after metabolic selection. The numbers of cardiomyocytes with single, double, and more than triple
nuclei are separately represented by the blue, red, and green bars, respectively.
(D) Action-potential recording of the purified hESC-CMs using microelectrodes. Shown are representative configurations of the nodal- (top), atrial- (middle), and
ventricular-like (bottom) action potentials.
(E) Drug responses in purified hESC-derived aggregates using the MEA system (top). The line graph (bottom) represents the chronotropic response against
b-agonist isoproterenol (green; n = 3) and muscarinic agonist carbamylcholine (orange; n = 3). All data were obtained from independent experiments.
(F) The teratoma-forming capacities of hESCs (1,000 cells), nonpurified hESC-derived cells (2.0 3 105 cells), and purified hESC-CMs (2.0 3 105 cells) were
evaluated through their transplantation into the testes of NOD-SCID mice. The bar graph represents the summarized results (hESCs, n = 10; nonpurified, n = 20;
purified, n = 20).
(G) Immunofluorescent staining for Oct3/4 in dispersed cells from nonpurified hESC-derived EBs. The bar graph shows numbers of hESC-like colonies obtained
from hESC-derived cells (2.0 3 105; n = 5).
Scale bars represent 50 mm (A and B), 100 mm (E and G), and 1 cm (F). *p < 0.05; **p < 0.01. Data are shown as mean ± SD. See also Figure S6.
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Metabolic Selection for PSC-Derived Cardiomyocytesfor biomass synthesis. Through our investigations, we eliminated
the possibility that lactate supplementation caused toxic extra-
cellular or intracellular acidification. We propose that these134 Cell Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc.differing properties may be a result of (1) the retrospective
glycolytic pathway consuming two ATP molecules during
conversion of a lactate molecule to G6P, and (2) ESCs not being
Cell Stem Cell
Metabolic Selection for PSC-Derived Cardiomyocytesable to effectively obtain ATP from glycolysis nor from OXPHOS
under glucose-depleted conditions. Therefore, activation of the
retrospective glycolytic pathway may accelerate a catastrophic
balance of ATP supply and demand in ESCs, whereas cardio-
myocytes can maintain cellular ATP homeostasis by producing
more ATP via a highly active OXPHOS mechanism (Hattori
et al., 2010).
A patient would theoretically require about 109 cardiomyo-
cytes in therapeutic applications of purified cardiomyocytes. In
this study, we obtained approximately 5 3 105 purified human
cardiomyocytes per 177 cm2 dish. Taking into account their
postpurification proliferative capacities, rough estimates there-
fore suggest that 1 3 109 cardiomyocytes could be obtained
from 800 dishes (14.13 m2). This scale is close to the capacity
of commercially available automatic large-scale culture systems
and suggests that combining more sophisticated differentiation
methods with our lactate method could facilitate realistic appli-
cation of PSC-derived cardiomyocytes to human therapy.
EXPERIMENTAL PROCEDURES
Animals
All animals including pregnant ICR mice, neonatal Wistar rats, and NOD-SCID
mice (8 weeks old, male) were purchased from CLEA Japan (Tokyo). All exper-
imental procedures and protocols were approved by the Animal Care and Use
Committee of Keio University and conformed to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Cells
Mouse ESCs were obtained from the Laboratory of Pluripotent Cell Studies,
RIKEN Center for Developmental Biology. The hESC line (KhES-2 and
KhES-3) was obtained from the Department of Development and Differentia-
tion, Institute for Frontier Medical Sciences, Kyoto University and used in
conformity with the Guidelines for Derivation and Utilization of Human Embry-
onic Stem Cells of the Ministry of Education, Culture, Sports, Science, and
Technology, Japan. The hiPSC line (253G4 and 201B7) was obtained from
the Center for iPSC Research and Application, Kyoto University. The skeletal
myoblast cell line (C2C12), hepatocyte cell line (HepG2), and renal cell line
(HEK293) were obtained from the American Type Culture Collection.
Reagents
The mouse monoclonal antibodies for a-actinin (immunoglobulin G1 [IgG1])
and Ki67 (IgM) were purchased from Sigma-Aldrich (Sigma). The mouse
monoclonal antibodies for SMA (IgG2a), bIII-tubulin, Oct3/4, and Tra1-60
were purchased from Dako, Promega, BD Transduction Laboratories, and
Millipore, respectively. The goat polyclonal antibodies for GATA-4 (C-20)
and Nkx2.5 (N-19) were purchased from Santa Cruz Biotechnology (Santa
Cruz). Alexa Fluor 488 and 546 anti-mouse IgG (IgG1, IgG2a, and IgM) antibody
and anti-goat IgG antibody were purchased from Invitrogen. DAPI and E-cad-
herin-Fc were also purchased from Invitrogen. Tetramethylrhodamine methyl
ester perchlorate (TMRM), mitotracker red, 20,70-bis-(2-carboxyethyl)-5-(and-
6)-carboxyfluorescein (BCECF) and Fluo-4 dye were purchased from Invitro-
gen. Fibronectin, isoproterenol hydrochloride, carbamylcholine, and a-CHC
were purchased from Sigma. The [13C]-labeled glucose and lactate were
purchased from Isotec. The [14C]-labeled lactate was purchased from
PerkinElmer.
Maintenance of Mouse and Human PSCs
We maintained mouse ESCs on gelatin- or E-cadherin-coated dishes in Glas-
gow minimum essential medium (MEM) (Sigma) supplemented with 10% fetal
bovine serum (FBS; Equitech-Bio), 0.1 mM MEM nonessential amino acid
solution (Sigma), 2 mM L glutamine (Sigma), 0.1 mM b-mercaptoethanol
(Sigma), and 2,000 U/ml murine leukemia inhibitory factor (Chemicon)
(Nagaoka et al., 2006). We maintained hESCs and hiPSCs on MEFs in Dulbec-
co’s modified Eagle’s medium/nutrient mixture F-12 Ham 1:1 (DMEM-F12;CeSigma) supplemented with 20% knockout serum replacement (Invitrogen),
0.1 mM MEM nonessential amino acid solution (Sigma), 2 mM L glutamine
(Sigma), 0.1 mM b-mercaptoethanol (Sigma), and 4 ng/ml basic fibroblast
growth factor (Wako).
Differentiation of Human PSC-Derived Cardiomyocytes
We cultured the enzymatically detached undifferentiated colonies of
hESCs and hiPSCs with aMEM (Wako Pure Chemical, Wako) that contained
50 mg/ml ascorbic acid, supplemented with 5% FBS (Biowest) and 0.1 mM
b-mercaptoethanol in bacterial Petri dishes for formation of EBs. EBs contain-
ing rhythmically beating cells were observed 14 to 20 days later. Typically,
1%–10% of EBs contained beating cells. Media were changed once a week.
EBs were used for purification experiments between days 20 and 30.
Purification of hESC- and hiPSC-Derived Cardiomyocytes
The selection medium was prepared before use. Glucose-free DMEM (no
glucose, no pyruvate; Invitrogen) supplemented with 4 mM lactate medium
was produced using 1 M lactate stock solution prepared from diluting 10 M
lactate (Wako Pure Chemical) with sterile 1M Na-HEPES (Sigma). The
human PSC-derived EBs at differentiation day 20 to 30 were extensively
washed with and exposed to the selection medium. Media were changed
every 2 or 3 days for eliminating dead cells via rapid flushing using
40 mm filters (Becton Dickinson). Cells were sampled daily from day 6 of
purification for optimizing the timing of harvest for each batch. We split
sampled cells into two experiments: one for test cultivation and another
for FACS analysis. In the test cultivation, cells were transferred to fibro-
nectin-coated dishes and cultured for several days with aMEM supple-
mented with 5% FBS. FACS analysis was performed using a-actinin
antibodies. Our criterion for determining the harvest day was at least
95% purity indicated by FACS analysis. All harvested cells were then trans-
ferred to fibronectin-coated dishes and cultured for several more days
under aMEM supplemented with 5% FBS, during which the media were
changed several times for complete removal of debris consisting of dead
cells and insoluble matrix. The purified cardiomyocytes were finally
collected by rapid flushing. Movies were recorded using a fluorescence
microscope (BZ-9000; Keyence).
Cardiomyocyte Purification Using Mitochondrial Dye for Gene Array
To prepare purified cardiomyocytes for the gene array, we used hearts from
neonatal mice (P1). Purification ofmouse neonatal cardiomyocytes usingmito-
chondrial TMRM dye was performed by FACS (FACS Aria; Becton Dickinson),
as described previously (Hattori et al., 2010).
Immunofluorescence
We fixed cells with 4% paraformaldehyde in PBS (pH 7.0) for 20 min. Subse-
quently, cells were permeabilized with 0.1% Triton X-100 (Sigma) at room
temperature for 10 min and then incubated with the primary antibody at 4C
overnight. Cells were then washed with Tris-buffered saline (TBS) containing
0.1% Tween 20 four times prior to incubation with the secondary antibodies
at room temperature for 1 hr. After nuclear staining with DAPI (Invitrogen),
stained cells were detected by fluorescence microscopy (IX71; Olympus) or
confocal-laser microscopy (LSM 5 DUO; Carl Zeiss).
Cell Viability under Glucose-Depleted Conditions with or without
Lactate
Neonatal cardiomyocytes, ESCs, and noncardiomyocytes including MEFs,
HepG2, HEK293, peripheral lymphatic cells, C2C12, skeletal myotubes,
and fetal neurons were exposed to glucose-free DMEM (Invitrogen)
supplemented with or without lactate (Wako). Cell viabilities were deter-
mined by the LIVE/DEAD Viability/Cytotoxicity Assay Kit (Invitrogen) based
on the simultaneous determination of live and dead cells with the calcein
AM and ethidium homodimer-1 probes. Fluorescence imaging of the cells
(live cells were labeled green, whereas the nuclei of dead cells were labeled
red) was performed with fluorescence microscopy (IX70 microscope;
Olympus) equipped with a color charge-coupled device camera (CS220;
Olympus). The green-labeled live area was measured using Image J.
Relative cell viabilities were calculated in percentages, compared with those
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Purified cardiomyocytes were completely dissociated by 0.25% trypsin-EDTA
and then fixed with 4%paraformaldehyde for 10min. Subsequently, cells were
permeabilized with 0.1% Triton X-100 (Sigma) at room temperature for 10 min
and then incubated with the sarcomeric a-actinin antibody (Sigma) for 3 hr.
Cells were washed with TBS containing 0.1% Tween 20 prior to incubation
with the Alexa Fluor 488 donkey anti-mouse IgG secondary antibody (Invitro-
gen) at room temperature for 2 hr. These cells were analyzed via FACS (EPICS
XL; Beckman Coulter).
Quantitative Real-Time PCR
Total RNA was extracted with ISOGEN reagent (Nippon Gene), and real-time
PCR was performed as described previously (Yuasa et al., 2005). For quanti-
tative analysis, complementary DNA (cDNA) was used as the template in a
TaqMan real-time PCR assay using the ABI Prism 7700 sequence detection
system (Applied Biosystems, Foster City, CA, USA) according to the manufac-
turer’s instructions. Data were normalized to GAPDH. Human heart, skeletal
muscle, and brain total RNA was purchased from Takara Bio. The primers
and TaqMan probe for human NANOG, POU5F1, ACTC1, NKX2.5, MYH6,
MYOD, AFP, MAP2, and GAPDH were Hs02387400_g1, Hs01895061_u1,
Hs00606316_m1, Hs00231763_m1, Hs00411908_m1, Hs02330075_g1,
Hs01040607_m1, Hs00258900_m1, and Hs02758991_g1, respectively.
Glucose Fluxome Analysis by Capillary Electrophoresis
and Mass Spectrometry
In neonatal cardiomyocytes, ESCs, and noncardiomyocytes including HepG2
and C2C12, the media were switched to modified DMEM supplemented with
10% FBS and 10 mM [13C]-labeled glucose (Isotec) instead of 10 mM glucose.
In 30 min, these cells were washed in 10% mannitol (Wako) and then plunged
into methanol that contained internal standards (300 mM each of methionine
sulfone for cations and MES for anions). Cells and the medium were collected
for capillary electrophoresis and mass spectrometry experiments using an
Agilent capillary electrophoresis system equipped with an air pressure
pump, an Agilent 1100 series mass selective detector mass spectrometer,
an Agilent 1100 series isocratic high-performance liquid-chromatography
pump, a G1603A Agilent capillary electrophoresis and mass spectrometry
adaptor kit, and a G1607A Agilent capillary electrophoresis and mass spec-
trometry sprayer kit (Agilent Technologies) as described previously (Endo
et al., 2009; Shintani et al., 2009). Values were corrected against cell numbers.
Lactate Fluxome Analysis by Capillary Electrophoresis
and Mass Spectrometry
In mouse ESCs, hESC-derived EBs, MEFs, and neonatal rat cardiomyocytes,
the medium was switched to modified glucose-free DMEM (Invitrogen)
supplemented with 4 mM [13C]-labeled lactate (Isotec). After 30 min and/or
24 hr, these cells were collected for analysis as described above. Values
were corrected against cell numbers.
Action-Potential Recordings Using Microelectrodes
The microscope was equipped with a recording chamber and a noise-free
heating plate (Micro Warm Plate; Kitazato Supply). Standard glass microelec-
trodes that had a DC resistance of 25–35 mega U when filled with pipette
solution (2 M KCl) were positioned using a motor-driven micromanipulator
(EMM-3SV; Narishige) under optical control. Spontaneously contracting
hESC-derived aggregates after metabolic selection were seeded and cultured
in fibronectin-coated dishes, and the action potentials were recorded. The
recording pipette was connected to a patch-clamp amplifier (Axopatch
200B; Axon Instruments), and the signal was passed through a low-pass filter
with a cutoff frequency of 2 kHz and digitized using an A/D converter with
a sampling frequency of 10 kHz (Digidata 1440A; Axon Instruments). Signals
were monitored, recorded as electronic files, and then analyzed offline with
pCLAMP 10 software (Axon Instruments).
Field-Potential Recordings Using the MEA System
To characterize the functional properties of our purified human PSC-derived
cardiomyocytes, we performed extracellular recording of field potentials using
the MEA system (Multi Channel Systems, Reutlingen, Germany) as described
previously (Tanaka et al., 2009; Zwi et al., 2009). To assess the effects of136 Cell Stem Cell 12, 127–137, January 3, 2013 ª2013 Elsevier Inc.different drugs on the electrophysiological properties, drug-diluted medium
was applied to the MEA culture plate. The applied drugs included isoproter-
enol hydrochloride and carbamylcholine. The temperature was maintained
at 37C during these recordings. For further evaluation of the effects of
temperature on the electrophysiological properties, temperatures were also
varied from 30C to 42C.
Teratoma Formation
To verify the elimination of immature cells with the potential to form teratomas
by purification, we transplanted 2.0 3 105 purified hESC-derived cardiomyo-
cytes, 2.0 3 105 nonpurified hESC-derived cells, and 1,000 undifferentiated
hESCs into the testes of immunocompromised NOD-SCID mice. Two months
after transplantation, animals were euthanized, and teratoma incidence was
evaluated.
Colony-Formation Assay
Nonpurified and purified hESC-derived cells (2.0 3 105) were completely
dissociated and cultured on theMEFswith PSCmaintenance culture condition
with 10 mM of ROCK inhibitor for 4 days. Then, immunofluorescence staining
for Oct3/4 and Tra1-60 was performed, and colony numbers were counted.
ATP Measurement
Cells were plated onto gelatin-coated 96-well white, clear-bottom culture
plates (Costar). After 2 days, cells were treated with the glucose-free plus
lactate medium for a given length of time. ATP levels were measured using
an ATP assay kit (Toyo Ink). In brief, 100 ml of the lysis and assay solution
provided by the manufacturer was added to the wells. After shaking for
1 min and incubating for 20 min at 23C, we measured luminescence of an
aliquot of the solution in a luminometer (Synergy 4; BioTek).
[14C]-Labeled Lactate Uptake
After washing the plates in glucose-free medium, cells were exposed to the
glucose-free plus 1 mM [14C]-labeled lactate condition. After 30 min, the cells
were washed three times in fresh medium and collected for analysis. [14C]
signal was detected by liquid scintillation analysis (Packard). Values were
corrected against cell number.
EdU Incorporation Assay
In one case, purified hESC-derived cardiomyocytes were dispersed and
seeded in the MEF precultured dishes and cultured with aMEM containing
5% FBS for 12 hr for attachment. They were then treated with 10 mM
EdU for 48 hr and processed according to the manufacturer’s instructions
(Invitrogen, Click-iT EdU Alexa Fluor 488 kit). The cells then underwent
additional immunofluorescent staining for a-actinin and were observed by
fluorescence microscopy. In another experimental setting, the intact floating
hESC-derived EBs were treated with 10 mM EdU for 48 hr, dispersed, and
then fixed with 4% paraformaldehyde followed by FACS analysis for deter-
mining the percentage of EdU-incorporated cells.
Statistical Analysis
All statistical analyses were performed using the Statistical Package for the
Social Sciences for Windows version 17 software (SPSS, Chicago). Values
are presented as mean ± SD. The statistical significance was evaluated using
Student’s t tests. A p value of less than 0.05 was considered statistically
significant.
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